Latest News Gedea Biotech announces the start of the clinical study VVC2025—first patients enrolledGedea Biotech today announced the start of the clinical study VVC2025, following approval from the Swedish Medical…5 March 2026Gedea Biotech strengthens IP portfolio with new European patent for treating infections with GDLGedea Biotech today announced that European patent no. 3 691 625 has entered into force, further strengthening Gedea’s…11 February 2026Gedea Biotech strengthens IP portfolio with new US patent for vaginal formulationGedea Biotech today announced that the company has been granted a US patent for its vaginal formulation (patent no.…4 February 2026Gedea Biotech appoints Julie Waras Brogren as new CEO to lead the company into its commercialization phaseGedea Biotech today announces a planned CEO transition. After close to ten years as CEO, Annette Säfholm has decided to…27 January 2026Gedea Biotech announce start of the clinical study BV2025 following CE marking of pHyph —first patients enrolledGedea Biotech today announced that the clinical trial BV2025 has started, following approval from the Swedish Medical…22 January 2026Gedea Biotech strengthens its Board with extensive commercial expertise to support next phaseLund, Sweden – November 18, 2025 Gedea Biotech, an innovative Swedish life science company in women’s health, today…18 November 2025New insights into the vaginal microbiome: Emilia Lahtinen’s industrial PhD journeyAt the intersection of academic research and biotech innovation, Emilia Lahtinen is pursuing her industrial PhD as a…6 November 2025 Press KitClick to download logos and images.
